deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 3-arm NCT03152318

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (rQNestin)

A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide

Sponsor: Candel Therapeutics, Inc.

Conditions Anaplastic Oligodendroglioma of Brain (Diagnosis) Astrocytoma Brain Cancer Brain Tumor Ependymoma Ganglioglioma Glioblastoma Glioblastoma Multiforme Glioma Malignant Astrocytoma Malignant Glioma of Brain Mixed Oligo-Astrocytoma Oligodendroglioma Pylocytic/Pylomyxoid Astrocytoma
Interventions Cyclophosphamide Stereotactic biopsy rQNestin
Updated 18 times since 2017 Last updated: Mar 2, 2026 Started: Jul 18, 2017 Primary completion: Jan 31, 2027 Completion: Jan 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03152318, this PHASE1 trial focuses on Anaplastic Oligodendroglioma of Brain (Diagnosis) and Astrocytoma and remains ongoing. Sponsored by Candel Therapeutics, Inc., it has been updated 18 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~May 2018 · 9 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2019 · 13 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Sep 2023 · 7 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – ~Mar 2026 · 7 months · monthly snapshot~Mar 2026 – present · 5 months · monthly snapshot

Change History

18 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Aug 2025 — Mar 2026 [monthly]

    Recruiting PHASE1

  3. Sep 2024 — Aug 2025 [monthly]

    Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  5. Sep 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

▶ Show 13 earlier versions

  1. Feb 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  2. Nov 2022 — Feb 2023 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  3. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  6. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. Mar 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  8. Sep 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  9. Aug 2018 — Sep 2019 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  11. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Aug 2017 — May 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  13. Jul 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Candel Therapeutics, Inc.
  • Dana-Farber Cancer Institute
  • National Institutes of Health (NIH)
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations